Clinical trials: COVID-19 Booster
Covid19
The Lymphoma and Leukemia Society Amended COVID-19 Registry
The LLS COVID-19 Registry is being amended to invite people who participated in the LLS COVID-19 Registry and did not develop antibodies after receiving a complete COVID-19 vaccination, as well as people with blood cancer who did…
- Trial name
- NCT04794387
- Testing
- Amended LLS COVID-19 Registry
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Blood Cancer United
COVID-19 Pandemic, Immunogenicity
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant.
- Conditions
- COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
- Trial name
- SH-MO-214 (NCT05383560)
- Testing
- mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, MRNA-1273.222 Vaccine
- Where
- Israel
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
COVID-19 Vaccine
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19
The purpose of this study is to assess the safety, tolerability, and immunogenicity of a booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT05216601
- Testing
- MVC-COV1901, MVC-COV1901(Beta)-15, MVC-COV1901(Beta)-25
- Where
- 2 sites in Taiwan
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19
To Evaluate Safety and Immunogenicity of a Prophylactic Plasmid DNA
Currently, several vaccines are available to combat the COVID-19 pandemic. The persistence of SARS-CoV-2 globally requires the development of additional vaccines to aid in preventing further SARS-CoV-2 infections.
- Trial name
- VAX-002-01 (NCT06436911)
- Testing
- COVIGENIX VAX- 002
- Where
- 6 sites in Canada
- Volunteers
- 46 people
- Sponsor
- Entos Pharmaceuticals Inc.
COVID-19
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a…
- Trial name
- NCT07536308
- Testing
- OCU500
- Where
- 6 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
This is a randomized, double-blind, active-controlled Phase Ⅲ clinical trial, as well as an immuno-bridging clinical trial by parallel testing previous serum after primary immunization of COVID-19 vaccine (Vero cell), inactivated…
- Trial name
- NCT05381350
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Where
- China
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV_Beta in healthy participants.
- Trial name
- NCT05389319
- Testing
- Prime-2-CoV_Beta
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
COVID-19
Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).
This is a single-blind, randomised controlled clinical trial to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccines (Pfizer-BioNTech or Moderna) as booster dose…
- Trial name
- MIACoV (NCT05228730)
- Testing
- Tozinameran - Standard dose, Tozinameran - fractional dose, Elasomeran - standard dose
- Where
- Australia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19, Sars-CoV-2 Infection
Phase 3 Booster Vaccination Against COVID-19
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac…
- Trial name
- NCT05077176
- Testing
- CoronaVac, Turkovac
- Where
- 41 sites in Turkey (Türkiye)
- Volunteers
- 4,340 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous…
- Trial name
- NCT05367895
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Brazil
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Solid Tumor Malignancy, Hematologic Malignancy
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems.
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma
- Trial name
- NCT04847050
- Testing
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
COVID-19, Vaccine Reaction
The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)
While both heterologous (mixing) and homologous (matching) vaccine regimens are now considered standard of care, post-vaccination complications and long-term effects of the different vaccination regimens have not been thoroughly…
- Conditions
- COVID-19, Vaccine Reaction, COVID-19 Pandemic
- Trial name
- BOOSTED (NCT05268185)
- Testing
- Moderna Booster Vaccine, Pfizer Booster Vaccine
- Where
- United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
COVID-19
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with…
- Trial name
- NCT05343871
- Testing
- Sinovac, AZD1222, BNT162b2
- Where
- 2 sites in Brazil, Pakistan
- Volunteers
- 2,354 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
COVID-19
Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)
The 2019 Coronavirus disease outbreak (COVID-19) was first reported at the end of 2019 in Wuhan China as a severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection.
- Trial name
- NCT05172193
- Testing
- SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
- Where
- 7 sites in Indonesia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
Vaccination Refusal
COVID-19 Booster Readiness Survey
The purpose of this administrative survey is to inform health system logistics by assessing the attitudes towards towards the bivalent COVID-19 boosters held by healthcare workers (HCWs) at a large, rural health system.
- Trial name
- NCT05529030
- Testing
- Salience of Omicron variant, Self-protection message, Other-protection message
- Where
- United States
- Volunteers
- 12,036 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
COVID-19
Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.
SARS-CoV-2 is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, collectively known as COVID-19.
- Trial name
- NCT05812586
- Testing
- SCB-2019/Clover, AstraZeneca/Fiocruz, Pfizer/Wyeth
- Where
- 2 sites in Brazil
- Volunteers
- 760 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine
Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O, Ad5-nCoV/O-IH or mRNA-based…
- Trial name
- NCT05442684
- Testing
- Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector), Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation, mRNA-based COVID-19 vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.